Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk has launched its type II diabetes treatment, Ryzodeg, in Mexico. This makes Mexico the first country where Ryzodeg is commercially available.
Moreover, Ryzodeg is the first approved drug comprising a combination of basal insulin and an ultra-long duration of action meal-time insulin in one pen for the treatment of type II diabetes. Being a combination drug, Ryzodeg requires lesser number of daily injections compared to the administration of basal and mealtime insulin in separate injections.
According to the press release issued by Novo Nordisk, more than 50% of type II diabetes patients who are treated with basal insulin fail to achieve their glycemic targets as measured by hemoglobin A1c. Some patients eventually require intensified insulin treatment through the addition of mealtime insulin (bolus therapy) to achieve or maintain their glycemic targets over time.
http://www.zacks.com/stock/news/145814/Novo-Nordisks-Ryzodeg-Now-in-Mexico-for-Type-II-Diabetes
Moreover, Ryzodeg is the first approved drug comprising a combination of basal insulin and an ultra-long duration of action meal-time insulin in one pen for the treatment of type II diabetes. Being a combination drug, Ryzodeg requires lesser number of daily injections compared to the administration of basal and mealtime insulin in separate injections.
According to the press release issued by Novo Nordisk, more than 50% of type II diabetes patients who are treated with basal insulin fail to achieve their glycemic targets as measured by hemoglobin A1c. Some patients eventually require intensified insulin treatment through the addition of mealtime insulin (bolus therapy) to achieve or maintain their glycemic targets over time.
http://www.zacks.com/stock/news/145814/Novo-Nordisks-Ryzodeg-Now-in-Mexico-for-Type-II-Diabetes